WO2001078786A3 - High affinity peptide-containing nanoparticles - Google Patents

High affinity peptide-containing nanoparticles Download PDF

Info

Publication number
WO2001078786A3
WO2001078786A3 PCT/US2001/012093 US0112093W WO0178786A3 WO 2001078786 A3 WO2001078786 A3 WO 2001078786A3 US 0112093 W US0112093 W US 0112093W WO 0178786 A3 WO0178786 A3 WO 0178786A3
Authority
WO
WIPO (PCT)
Prior art keywords
high affinity
containing nanoparticles
affinity peptide
peptide moieties
polymeric nanoparticles
Prior art date
Application number
PCT/US2001/012093
Other languages
French (fr)
Other versions
WO2001078786A2 (en
Inventor
Stephen E Barry
Dominic Casenas
Rachel Decor
Andrew A Goodwin
Kevin Lindquist
Original Assignee
Alnis Biosciences Inc
Stephen E Barry
Dominic Casenas
Rachel Decor
Andrew A Goodwin
Kevin Lindquist
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US19776500P priority Critical
Priority to US60/197,765 priority
Priority to US22006100P priority
Priority to US60/220,061 priority
Priority to US60/220,530 priority
Priority to US22053000P priority
Priority to US60/236,448 priority
Priority to US23644800P priority
Priority to US60/256,819 priority
Priority to US25689400P priority
Priority to US25689500P priority
Priority to US25681900P priority
Priority to US60/256,894 priority
Priority to US60/256,985 priority
Priority to US60/261,520 priority
Priority to US26152001P priority
Application filed by Alnis Biosciences Inc, Stephen E Barry, Dominic Casenas, Rachel Decor, Andrew A Goodwin, Kevin Lindquist filed Critical Alnis Biosciences Inc
Priority claimed from JP2001576085A external-priority patent/JP2004500438A/en
Priority claimed from US10/257,455 external-priority patent/US20040126900A1/en
Publication of WO2001078786A2 publication Critical patent/WO2001078786A2/en
Publication of WO2001078786A3 publication Critical patent/WO2001078786A3/en

Links

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer

Abstract

The present invention is directed to polymeric nanoparticles functionalized with two or more peptide moieties that possess high affinity to biomolecular targets, the peptide moieties being covalently linked to the nanoparticle polymeric core structure, either directly or via a linker molecule. The invention is further directed to methods of synthesizing these polymeric nanoparticles and to the various applications for which they may be used.
PCT/US2001/012093 2000-04-14 2001-04-13 High affinity peptide-containing nanoparticles WO2001078786A2 (en)

Priority Applications (16)

Application Number Priority Date Filing Date Title
US19776500P true 2000-04-14 2000-04-14
US60/197,765 2000-04-14
US22006100P true 2000-07-21 2000-07-21
US60/220,061 2000-07-21
US22053000P true 2000-07-24 2000-07-24
US60/220,530 2000-07-24
US23644800P true 2000-09-29 2000-09-29
US60/236,448 2000-09-29
US25689400P true 2000-12-18 2000-12-18
US25689500P true 2000-12-18 2000-12-18
US25681900P true 2000-12-18 2000-12-18
US60/256,894 2000-12-18
US60/256,985 2000-12-18
US60/256,819 2000-12-18
US26152001P true 2001-01-12 2001-01-12
US60/261,520 2001-01-12

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AU5535601A AU5535601A (en) 2000-04-14 2001-04-13 High affinity peptide-containing nanoparticles
CA002406395A CA2406395A1 (en) 2000-04-14 2001-04-13 High affinity peptide-containing nanoparticles
JP2001576085A JP2004500438A (en) 2000-04-14 2001-04-13 High affinity of the peptide-containing nanoparticles
US10/257,455 US20040126900A1 (en) 2001-04-13 2001-04-13 High affinity peptide- containing nanoparticles
EP01928507A EP1276507A2 (en) 2000-04-14 2001-04-13 High affinity peptide-containing nanoparticles

Publications (2)

Publication Number Publication Date
WO2001078786A2 WO2001078786A2 (en) 2001-10-25
WO2001078786A3 true WO2001078786A3 (en) 2002-08-15

Family

ID=27575157

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/012093 WO2001078786A2 (en) 2000-04-14 2001-04-13 High affinity peptide-containing nanoparticles

Country Status (4)

Country Link
EP (1) EP1276507A2 (en)
AU (1) AU5535601A (en)
CA (1) CA2406395A1 (en)
WO (1) WO2001078786A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2487720A1 (en) * 2002-06-03 2003-12-11 Alnis Biosciences, Inc. Therapeutic agent-containing polymeric nanoarticles
BRPI0510568B1 (en) * 2004-05-05 2016-11-22 Firmenich & Cie copolymer, process for preparing the same, biodegradable particle, using the same process for preparing a delivery system for perfuming composition, and perfumed product
US8231907B2 (en) 2006-03-21 2012-07-31 Morehouse School Of Medicine Nanoparticles for delivery of active agents
CN103665117B (en) * 2013-12-03 2015-07-01 南昌大学 Method for high-efficiency purification of water soluble nano silver particle-streptavidin conjugate
CN103665118B (en) * 2013-12-03 2015-11-25 南昌大学 Purification of the water-soluble iron oxide nanoparticles streptavidin-biotin conjugate method

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5904936A (en) * 1995-03-28 1999-05-18 Flamel Technologies Particles based on polyamino acid(s) and capable of being used as delivery vehicles for active principle(s) and method for preparing them

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5904936A (en) * 1995-03-28 1999-05-18 Flamel Technologies Particles based on polyamino acid(s) and capable of being used as delivery vehicles for active principle(s) and method for preparing them

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DAVIS S S: "Biomedical applications of nanotechnology - implications for drug targeting and gene therapy", TRENDS IN BIOTECHNOLOGY, ELSEVIER PUBLICATIONS, CAMBRIDGE, GB, vol. 15, no. 6, 1 June 1997 (1997-06-01), pages 217 - 224, XP004064510, ISSN: 0167-7799 *
HARRIS E ET AL: "Preparation and in vitro characterisation of biodegradable cyclosporin-loaded micro- and nanoparticles", JOURNAL OF CONTROLLED RELEASE, ELSEVIER SCIENCE PUBLISHERS B.V. AMSTERDAM, NL, vol. 46, no. 1, 5 May 1997 (1997-05-05), pages 190, XP004055754, ISSN: 0168-3659 *
JAGUR-GRODZINSKI J: "Biomedical application of functional polymers", REACTIVE & FUNCTIONAL POLYMERS, ELSEVIER SCIENCE PUBLISHERS BV, NL, vol. 39, no. 2, 15 February 1999 (1999-02-15), pages 99 - 138, XP004160680, ISSN: 1381-5148 *
LEMOINE D ET AL: "Polymeric nanoparticles as delivery system for influenza virus glycoproteins", JOURNAL OF CONTROLLED RELEASE, ELSEVIER SCIENCE PUBLISHERS B.V. AMSTERDAM, NL, vol. 54, no. 1, 1 June 1998 (1998-06-01), pages 15 - 27, XP004127852, ISSN: 0168-3659 *

Also Published As

Publication number Publication date
EP1276507A2 (en) 2003-01-22
CA2406395A1 (en) 2001-10-25
WO2001078786A2 (en) 2001-10-25
AU5535601A (en) 2001-10-30

Similar Documents

Publication Publication Date Title
Slocik et al. Synthesis of gold nanoparticles using multifunctional peptides
AU2002249833A1 (en) Foam including surface-modified nanoparticles
WO2004044281A3 (en) Nano-porous fibers and protein membranes
CA2359318A1 (en) Biomaterials formed by nucleophilic addition reaction to conjugated unsaturated groups
HRP20120794T1 (en) Process for preparing maytansinoid antibody conjugates
AU2001261841A1 (en) Coated nanoparticles
WO2002070589A3 (en) Preparation of polymer nanocomposites by dispersion destabilization
WO2005118702A3 (en) Unagglomerated core/shell nanocomposite particles
WO2001073123A3 (en) Nanoparticles having oligonucleotides attached thereto and uses therefor
AU2002355727A1 (en) Multi-layer composites formed from compositions having improved adhesion, coating compositions, and methods related thereto
CA2403620A1 (en) Inorganic chromophore bioconjugates
WO2003031581A3 (en) Thioester-terminated water soluble polymers and method of modifying the n-terminus of a polypeptide therewith
WO2007004067A3 (en) Methods and compositions for the delivery of biologically active agents
CA2419138A1 (en) Pmma moulding compositions with better impact strength
WO2001037803A3 (en) Responsive polymeric hollow particles
WO2007015105A3 (en) Nanoparticles comprising antibacterial ligands
BR0318060A (en) Composition, article, and method for imparting stain-release characteristics to a fibrous substrate
RU2001123542A (en) Hybrid fine-grained scalable video coding with signal / noise ratio of the time-dependent
WO2004016274B1 (en) Novel peptide-conjugated oligomeric compounds
MXPA05002429A (en) Nanoparticles, method for modifying their surfaces, dispersion of nanoparticles, method for the production and the utilization thereof.
SI1935427T1 (en) Uses of soluble CTLA4 mutant molecules
RU2004133894A (en) Functionalized nanoparticles and methods for their use
RU2008121393A (en) Carbon nanotubes functionalized fullerenes
EP1355919A4 (en) Molecules with extended half-lives, compositions and uses thereof
AU2001272993A1 (en) Multianalyte molecular analysis

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2001255356

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2406395

Country of ref document: CA

ENP Entry into the national phase in:

Ref country code: JP

Ref document number: 2001 576085

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2001928507

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001928507

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10257455

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 2001928507

Country of ref document: EP